Sensus Healthcare, Inc. Units Separate; Trading of Common Stock and Warrants Commences
BOCA RATON, Fla., July 25, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today reported the separation of the 2,300,000 units issued in its underwritten initial public offering in accordance with their terms. […]
Sensus Healthcare, Inc. Announces Separation of Units Sold in IPO
BOCA RATON, Fla., July 21, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that the 2,300,000 units issued in its underwritten initial public offering will separate in accordance with their terms […]
The SRT-100™ Beats The Keloid Scar
A quick question for you–what do you tell your patients when they come into your office and inform you that they have a keloid scar they want to get rid of? Do you offer a surgical solution that will result in them going under the knife and being stitched up? If your patient is aichmophobic, […]
SRT – The Best Keloid Scar Treatment!
SRT is the best keloid scar treatment on the market. Keloids form after the skin has been injured and the growth of fibrous tissue, more commonly known as scar tissue, begins to grow excessively. These unsightly, smooth, yet hard colonies of scar tissue are found mostly on the shoulders, cheeks, earlobes, and chest but can […]
